Strategies for Success: Optimizing Antiretroviral Therapy in Heavily Treatment–Experienced Patients

Here’s my take on how to optimize the switching of antiretroviral therapy in patients with virologic suppression and a history of antiretroviral resistance.

Paul E. Sax, MD Released: October 17, 2022

Here’s why I think using newer novel agents earlier could affect virologic suppression and mortality for people with multidrug-resistant HIV.

Josep M. Llibre, MD, PhD Released: November 17, 2022

Lenacapavir is from a new drug class and may be a promising component of antiretroviral therapy if adherence can be ensured.

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP Released: January 5, 2023

Here are my thoughts on the role of proviral DNA genotypic resistance testing for treatment-experienced people with HIV when switching ART in the setting of viral suppression, including when switching to long-acting ART.

José R. Arribas, MD Released: February 6, 2023

Gain expert insight on the fundamentals of managing this patient population with difficult-to-treat disease, including analysis of resistance, latest guideline recommendations, and construction of new ART regimens.

Eric S. Daar, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Pharmacists: 1.0 contact hour (0.1 CEUs) Released: October 6, 2022 Expired: No longer available for credit

Review downloadable slides on ART for highly treatment–experienced patients, including analysis of resistance, latest guideline recommendations, and construction of new ART regimens.

Eric S. Daar, MD Released: October 5, 2022

In this case-based video module, learn the latest data and recommendations for switching ART in patients with a history of resistance who are currently virologically suppressed.

Paul E. Sax, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 20, 2022 Expired: No longer available for credit

In this case-based video module, learn the latest data and recommendations for switching ART in patients with a history of resistance who are currently virologically suppressed.

Paul E. Sax, MD Released: October 20, 2022

In this case-based video module, learn the latest data and recommendations for creating salvage regimens for heavily treatment–experienced patients that include high-barrier antiretrovirals.

Christine Katlama, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Pharmacists: 0.5 contact hours (0.05 CEUs) Released: November 11, 2022 Expired: No longer available for credit

Review downloadable slides on the latest data and recommendations for creating salvage regimens for heavily treatment–experienced patients that include high-barrier antiretrovirals.

Christine Katlama, MD Released: November 11, 2022

In this case-based video module, learn the causes of ART failure and the recommendations for managing it.

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Pharmacists: 0.5 contact hours (0.05 CEUs) Released: December 23, 2022 Expired: No longer available for credit

Review downloadable slides on the causes of ART failure and recommendations for managing it.

Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP Released: December 23, 2022

In this case-based video module, learn the latest data and guideline recommendations for using novel antiretroviral agents to construct new ART regimens for treatment-experienced PWH.

Josep M. Llibre, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 16, 2022 Expired: No longer available for credit

Review downloadable slides on the latest data and guideline recommendations for using novel antiretroviral agents to construct new ART regimens for treatment-experienced PWH.

Josep M. Llibre, MD, PhD Released: December 16, 2022

In this case-based video module, learn about the data and recommendations for using proviral DNA genotyping to help inform antiretroviral therapy decisions for treatment-experienced people with HIV.

José R. Arribas, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 23, 2022 Expired: No longer available for credit

Review downloadable slides on the data and recommendations for using proviral DNA genotyping to help inform antiretroviral therapy decisions for treatment-experienced people with HIV.

José R. Arribas, MD Released: December 23, 2022

In this case-based video module, learn the data and recommendations for the use of lenacapavir in ART salvage regimens for heavily treatment–experienced people with HIV.

Babafemi Taiwo, MBBS Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 3, 2023 Expired: No longer available for credit

Review downloadable slides on the data and recommendations for the use of lenacapavir in ART salvage regimens for heavily treatment–experienced people with HIV.

Babafemi Taiwo, MBBS Released: January 3, 2023